Matthew J. Maurer

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq et al. · Blood · 2017 · 1.7K citations · Full text

Medicine, Hematology, Oncology +10

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Carla Casulo, Michelle Byrtek, Keith Dawson et al. · Journal of Clinical Oncology · 2015 · 844 citations · Full text

Medicine, Immunology, Oncology +11

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer et al. · Journal of Clinical Oncology · 2005 · 696 citations · Full text

Pharmacy, Oncology, Pharmacology +15

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes

Edgardo R. Parrilla Castellar, Elaine S. Jaffe, Jonathan Said et al. · Blood · 2014 · 466 citations · Full text

Medicine, Oncology, Pathology +16

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung et al. · Journal of Clinical Oncology · 2019 · 423 citations

Medicine, Oncology, Chemotherapy +10